General Dermatology

In case you missed it, this week we had news about HyBryte's treatment success in CTCL patients, the impact of the COVID-19 pandemic on BCC surgeries, the FDA approval of dupilumab for H1 antihistamine-refractory CSU, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

As a patient with rosacea herself, Anastasia Georgievskaya highlights the innovation of Generative Skin in patient education.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Pelthos and Channel Therapeutics will merge to form a new publicly traded entity focused on commercializing the first at-home treatment for molluscum.

Haut.AI’s new tool promotes inclusive and realistic conversations on the power of skincare products, according to the CEO.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

This review of the latest dermatologic studies includes insights into dermatologic associations in patients with Crohn disease, the prevalence of tinea pedis in pediatric populations, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.

In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

Explore the top headlines of the week including insights on infection risks, drug updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about Alphyn Biologics' first patient dosed with zabalafin hydrogel, abrocitinib for Netherton Syndrome, the ICONIC-LEAD phase 3 study, and more.

This week, we feature top articles from our sister publications on FDA approvals, innovative tech updates, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The presentation, led by Amy Paller, MS, MD, highlighted the upcoming phase 3 SELVA study for microcystic lymphatic malformations.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Google search trends and TikTok view counts were used to analyze the public popularity of cosmeceutical ingredients like retinol, hyaluronic acid, and niacinamide.

Henry Lim, MD, discusses the ILDS’ renewed WHO relations status and the global crisis of corticosteroid misuse in skin-bleaching products.